Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
Personalis (PSNL) reported preliminary unaudited revenue of approximately $84.6 million for full year 2024, marking a 15% increase from 2023's $73.5 million and exceeding previous guidance of $83.0-84.0 million. The company's pharma tests, services, and enterprise sales revenue grew 20% to $77.2 million, despite a 20% decrease in Natera revenue to $25.4 million.
Fourth quarter 2024 revenue was $16.8 million, down 15% year-over-year, primarily due to declining revenue from Natera and VA MVP. The company delivered 1,441 molecular tests in Q4 2024, up 52% from Q3. Cash position stood at approximately $185.0 million, including a $50 million strategic investment from Merck. The company also secured a long-term commercial collaboration with Moderna.
Personalis (PSNL) ha riportato un fatturato preliminare non verificato di circa $84,6 milioni per l'intero anno 2024, segnando un aumento del 15% rispetto ai $73,5 milioni del 2023 e superando le precedenti previsioni di $83,0-84,0 milioni. I ricavi dei test, servizi e vendite nel settore farmaceutico della società sono aumentati del 20% a $77,2 milioni, nonostante una diminuzione del 20% dei ricavi di Natera, scesi a $25,4 milioni.
I ricavi del quarto trimestre 2024 ammontano a $16,8 milioni, in calo del 15% rispetto all'anno precedente, principalmente a causa della diminuzione dei ricavi provenienti da Natera e VA MVP. L'azienda ha effettuato 1.441 test molecolari nel Q4 2024, in crescita del 52% rispetto al Q3. La posizione di liquidità è stata di circa $185,0 milioni, inclusi $50 milioni di investimento strategico da Merck. Inoltre, l'azienda ha siglato una collaborazione commerciale a lungo termine con Moderna.
Personalis (PSNL) reportó ingresos preliminares no auditados de aproximadamente $84.6 millones para el año completo 2024, marcando un aumento del 15% en comparación con los $73.5 millones de 2023 y superando la guía previa de $83.0-84.0 millones. Los ingresos de pruebas farmacéuticas, servicios y ventas empresariales de la compañía crecieron un 20% a $77.2 millones, a pesar de una disminución del 20% en los ingresos de Natera, que alcanzaron los $25.4 millones.
Los ingresos del cuarto trimestre de 2024 fueron de $16.8 millones, una disminución del 15% interanual, principalmente debido a la reducción de ingresos de Natera y VA MVP. La compañía realizó 1,441 pruebas moleculares en el Q4 2024, un incremento del 52% con respecto al Q3. La posición de efectivo se situó en aproximadamente $185.0 millones, incluyendo una inversión estratégica de $50 millones por parte de Merck. También se aseguró una colaboración comercial a largo plazo con Moderna.
Personalis (PSNL)는 2024년 전체 매출이 약 8,460만 달러에 이를 것으로 예상된다고 보고하며, 이는 2023년의 7,350만 달러에 비해 15% 증가한 수치이며, 이전에 예측된 8,300만-8,400만 달러를 초과하는 결과입니다. 이 회사의 제약 테스트, 서비스 및 기업 매출은 20% 증가해 7,720만 달러에 달했으며, Natera의 매출은 20% 감소하여 2,540만 달러가 되었습니다.
2024년 4분기 매출은 1,680만 달러로, 전년 대비 15% 감소하였으며, 이는 주로 Natera 및 VA MVP로부터의 매출 감소가 원인입니다. 회사는 2024년 Q4에 1,441개의 분자 테스트를 제공하였고, 이는 Q3에 비해 52% 증가한 수치입니다. 현금 보유액은 약 1억 8천5백만 달러로, Merck로부터 5천만 달러의 전략적 투자를 포함하고 있습니다. 또한 이 회사는 Moderna와의 장기 상업 협력을 확보했습니다.
Personalis (PSNL) a annoncé un chiffre d'affaires préliminaire non audité d'environ 84,6 millions de dollars pour l'année entière 2024, marquant une augmentation de 15% par rapport aux 73,5 millions de dollars de 2023 et dépassant les prévisions précédentes de 83,0-84,0 millions de dollars. Les revenus des tests pharmaceutiques, des services et des ventes en entreprise de la société ont augmenté de 20% pour atteindre 77,2 millions de dollars, malgré une baisse de 20% des revenus de Natera, tombés à 25,4 millions de dollars.
Les revenus du quatrième trimestre 2024 se sont chiffrés à 16,8 millions de dollars, en baisse de 15% par rapport à l'année précédente, principalement en raison de la diminution des revenus de Natera et de VA MVP. L'entreprise a effectué 1 441 tests moléculaires au T4 2024, en hausse de 52% par rapport au T3. La position de trésorerie était d'environ 185,0 millions de dollars, incluant un investissement stratégique de 50 millions de dollars de Merck. L'entreprise a également sécurisé une collaboration commerciale à long terme avec Moderna.
Personalis (PSNL) berichtete von vorläufigen, nicht geprüften Einnahmen von etwa 84,6 Millionen Dollar für das gesamte Jahr 2024, was einem 15% Anstieg gegenüber 73,5 Millionen Dollar im Jahr 2023 entspricht und die vorherige Prognose von 83,0-84,0 Millionen Dollar übertrifft. Der Erlös aus den pharmazeutischen Tests, Dienstleistungen und Unternehmensverkäufen wuchs um 20% auf 77,2 Millionen Dollar, trotz eines Rückgangs der Einnahmen von Natera um 20% auf 25,4 Millionen Dollar.
Die Einnahmen im vierten Quartal 2024 beliefen sich auf 16,8 Millionen Dollar, was einem Rückgang von 15% im Jahresvergleich entspricht, hauptsächlich bedingt durch sinkende Einnahmen von Natera und VA MVP. Das Unternehmen führte im Q4 2024 1.441 molekulare Tests durch, was einem Anstieg von 52% im Vergleich zum Q3 entspricht. Die Barmittel beliefen sich auf etwa 185,0 Millionen Dollar, einschließlich einer strategischen Investition von 50 Millionen Dollar von Merck. Zudem sicherte sich das Unternehmen eine langfristige kommerzielle Zusammenarbeit mit Moderna.
- Full year revenue increased 15% to $84.6M, exceeding guidance
- Pharma tests and services revenue grew 20% to $77.2M
- Molecular test volume increased 52% quarter-over-quarter to 1,441 tests
- Secured $50M strategic investment from Merck
- Established commercial collaboration with Moderna
- Q4 2024 revenue decreased 15% year-over-year to $16.8M
- Natera revenue declined 20% to $25.4M for full year
- VA MVP revenue decreased 21% to $7.4M
- Q4 pharma tests and services revenue dropped 11% year-over-year
Insights
The 15% YoY revenue growth to
The
Key risk factors include the continued decline in Natera revenue and VA MVP business. However, the growing pharma/enterprise segment and strategic partnerships could offset these challenges in 2025.
The precision oncology market dynamics are evident in this report. The
Strategic partnerships with industry giants Moderna and Merck represent significant validation. These collaborations position Personalis to capture larger market share in the expanding precision medicine landscape. The declining Natera revenue suggests a strategic pivot towards higher-value pharma partnerships and enterprise customers.
For investors, the company's transition from revenue concentration risk (Natera, VA MVP) to a more diversified customer base with blue-chip partners indicates a maturing business model. The path to cash flow break-even, supported by the strong cash position, reduces near-term financing risk.
Full year revenue of
Cash balance of
Preliminary Full Year 2024 Revenue
-
Revenue of approximately
$84.6 million $73.5 million 15% , and above the company’s previous full year guidance range of$83.0 $84.0 million -
Revenue from pharma tests and services, enterprise sales, and other customers of approximately
$77.2 million $64.1 million 20% , despite revenue from Natera decreasing20% to approximately$25.4 million -
Revenue from population sequencing for the
U.S. Department of Veterans Affairs Million Veterans Program (VA MVP) of approximately$7.4 million $9.4 million 21%
Preliminary Fourth Quarter Revenue, Cash Balance, and Clinical Volume
-
Revenue of approximately
$16.8 million $19.7 million 15% , primarily due to the expected decline in revenue from Natera and the VA MVP -
Revenue from pharma tests and services, enterprise sales, and other customers of approximately
$16.6 million $18.7 million 11% , which includes the expected decrease in revenue from Natera of41% to approximately$4.2 million -
Cash, cash equivalents, and short-term investments of approximately
$185.0 million $50 million -
Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of
52% compared with 945 tests delivered in the third quarter of 2024
“In 2024, we grew annual revenue approximately
The above information is preliminary and subject to Personalis’ normal quarter and year-end accounting procedures and external audit by the company's independent registered public accounting firm. In addition, these preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2024, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “anticipate,” “estimate,” “expect,” “if,” “may,” “future,” “will” or similar expressions. These statements include statements relating to: Personalis’ fourth quarter and full year 2024 preliminary revenue and cash position as of December 31, 2024, increased revenue enabling achievement of Personalis’ current or future priorities, milestones and prospects, and the potential for Personalis to achieve cashflow break-even in the future. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from Moderna, Merck, and VA MVP; the success of Personalis’ clinical sales team’s and Tempus AI, Inc.’s sales and marketing efforts; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT platform; the rate of adoption and use of the NeXT platform; the expected benefits of Personalis’ extended collaboration with Moderna; Personalis’ ability to obtain Medicare coverage and reimbursement; and Personalis may opportunistically raise additional capital through equity offerings, debt financings, collaborations, or licensing arrangements. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on February 28, 2024, as updated by Personalis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 8, 2024, Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 7, 2024, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107686915/en/
Investor Relations Contact:
Caroline Corner
investors@personalis.com
646-277-1279
Media:
pr@personalis.com
Source: Personalis, Inc.
FAQ
What was Personalis (PSNL) full year revenue for 2024?
How much did Personalis (PSNL) receive from Merck's strategic investment?
What was PSNL's molecular test volume in Q4 2024?
How much did Personalis (PSNL) revenue from Natera decrease in 2024?
What was PSNL's cash position at the end of 2024?
